212 related articles for article (PubMed ID: 37099027)
1. Report of consensus panel 1 from the 11
Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
[TBL] [Abstract][Full Text] [Related]
2. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
D'Sa S; Matous JV; Advani R; Buske C; Castillo JJ; Gatt M; Kapoor P; Kersten MJ; Leblond V; Leiba M; Palomba ML; Paludo J; Qiu L; Sarosiek S; Shadman M; Talaulikar D; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Trotman J; Varettoni M; Vos J; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Kastritis E
Semin Hematol; 2023 Mar; 60(2):80-89. PubMed ID: 37147252
[TBL] [Abstract][Full Text] [Related]
3. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.
Leblond V; Kastritis E; Advani R; Ansell SM; Buske C; Castillo JJ; García-Sanz R; Gertz M; Kimby E; Kyriakou C; Merlini G; Minnema MC; Morel P; Morra E; Rummel M; Wechalekar A; Patterson CJ; Treon SP; Dimopoulos MA
Blood; 2016 Sep; 128(10):1321-8. PubMed ID: 27432877
[TBL] [Abstract][Full Text] [Related]
4. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
Merlini G; Sarosiek S; Benevolo G; Cao X; Dimopoulos M; Garcia-Sanz R; Gatt ME; Fernandez de Larrea C; San-Miguel J; Treon SP; Minnema MC
Semin Hematol; 2023 Mar; 60(2):113-117. PubMed ID: 37099030
[TBL] [Abstract][Full Text] [Related]
5. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.
Terpos E; Branagan AR; García-Sanz R; Trotman J; Greenberger LM; Stephens DM; Morel P; Kimby E; Frustaci AM; Hatjiharissi E; San-Miguel J; Dimopoulos MA; Treon SP; Leblond V
Semin Hematol; 2023 Mar; 60(2):107-112. PubMed ID: 37099029
[TBL] [Abstract][Full Text] [Related]
6. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.
Tam CS; Kapoor P; Castillo JJ; Buske C; Ansell SM; Branagan AR; Kimby E; Li Y; Palomba ML; Qiu L; Shadman M; Abeykoon JP; Sarosiek S; Vos J; Yi S; Stephens D; Roos-Weil D; Roccaro AM; Morel P; Munshi NC; Anderson KC; San-Miguel J; Garcia-Sanz R; Dimopoulos MA; Treon SP; Kersten MJ
Semin Hematol; 2023 Mar; 60(2):118-124. PubMed ID: 37099031
[TBL] [Abstract][Full Text] [Related]
7. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
Treon SP; Tedeschi A; San-Miguel J; Garcia-Sanz R; Anderson KC; Kimby E; Minnema MC; Benevolo G; Qiu L; Yi S; Terpos E; Tam CS; Castillo JJ; Morel P; Dimopoulos M; Owen RG
Semin Hematol; 2023 Mar; 60(2):97-106. PubMed ID: 37173155
[TBL] [Abstract][Full Text] [Related]
8. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Kapoor P; Paludo J; Abeykoon JP
Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
[TBL] [Abstract][Full Text] [Related]
9. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
14. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz R; Varettoni M; Jiménez C; Ferrero S; Poulain S; San-Miguel JF; Guerrera ML; Drandi D; Bagratuni T; McMaster M; Roccaro AM; Roos-Weil D; Leiba M; Li Y; Qiu L; Hou J; De Larrea CF; Castillo JJ; Dimopoulos M; Owen RG; Treon SP; Hunter ZR
Semin Hematol; 2023 Mar; 60(2):90-96. PubMed ID: 37099028
[TBL] [Abstract][Full Text] [Related]
15. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
16. Current approach to Waldenström Macroglobulinemia.
Ravi G; Kapoor P
Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
18. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
19. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
20. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
